ARCHIVES

Large Phase III Trial Seeks Optimal Use Of Tykerb vs. Herceptin In Breast Cancer

This article is from The Cancer Letter archive.

Vol. 31 No. 2 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

Regulatory Agencies: FDA Proposes “Treatment IDE” Funding Opportunities:

February 7, 1997

ASCO Annual Meeting: PARP Inhibitors Show Promise Against Breast Cancer In Small Phase II Studies

June 5, 2009

Max Wicha Describes Michigan’s Restructuring Planning For Growth

May 7, 1999

Avon Gives $3 Million To Expand CDC’s Screening Program

February 18, 1994

DCT Board Committee Recommends Limited Start On In Vitro Screening Program

January 18, 1985

GM Corp, to Reimburse Marrow Transplants for Breast Cancer

March 15, 1996